These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
151 related items for PubMed ID: 1974168
61. Clinicopathologic and Immunohistochemical Study of Combined Small Cell Carcinoma and Urothelial Carcinoma Molecular Subtype. Xiao GQ, Barrett MM, Yang Q, Unger PD. Pathol Oncol Res; 2019 Jul; 25(3):889-895. PubMed ID: 29249035 [Abstract] [Full Text] [Related]
62. Interaction of cytokeratin 19 head domain and HER2 in the cytoplasm leads to activation of HER2-Erk pathway. Ohtsuka T, Sakaguchi M, Yamamoto H, Tomida S, Takata K, Shien K, Hashida S, Miyata-Takata T, Watanabe M, Suzawa K, Soh J, Youyi C, Sato H, Namba K, Torigoe H, Tsukuda K, Yoshino T, Miyoshi S, Toyooka S. Sci Rep; 2016 Dec 23; 6():39557. PubMed ID: 28008968 [Abstract] [Full Text] [Related]
63. Overexpression of HER-2 in MDA-MB-435/LCC6 Tumours is Associated with Higher Metabolic Activity and Lower Energy Stress. Dragowska WH, Ginj M, Kozlowski P, Yung A, Ruth TJ, Adam MJ, Sossi V, Bally MB, Yapp DT. Sci Rep; 2016 Jan 04; 6():18537. PubMed ID: 26727049 [Abstract] [Full Text] [Related]
64. Molecular understanding of lung cancers-A review. Singh CR, Kathiresan K. Asian Pac J Trop Biomed; 2014 May 04; 4(Suppl 1):S35-41. PubMed ID: 25183110 [Abstract] [Full Text] [Related]
65. When Good Turns Bad: Regulation of Invasion and Metastasis by ErbB2 Receptor Tyrosine Kinase. Brix DM, Clemmensen KK, Kallunki T. Cells; 2014 Jan 27; 3(1):53-78. PubMed ID: 24709902 [Abstract] [Full Text] [Related]
66. HER2 protein overexpression and gene amplification in upper urinary tract urothelial carcinoma-an analysis of 171 patients. Sasaki Y, Sasaki T, Kawai T, Morikawa T, Matsusaka K, Kunita A, Kume H, Aoki I, Homma Y, Fukayama M. Int J Clin Exp Pathol; 2014 Jan 27; 7(2):699-708. PubMed ID: 24551292 [Abstract] [Full Text] [Related]
68. Active targeting using HER-2-affibody-conjugated nanoparticles enabled sensitive and specific imaging of orthotopic HER-2 positive ovarian tumors. Satpathy M, Wang L, Zielinski R, Qian W, Lipowska M, Capala J, Lee GY, Xu H, Wang YA, Mao H, Yang L. Small; 2014 Feb 12; 10(3):544-55. PubMed ID: 24038985 [Abstract] [Full Text] [Related]
69. Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy. Kaumaya PT, Foy KC. Future Oncol; 2012 Aug 12; 8(8):961-87. PubMed ID: 22894670 [Abstract] [Full Text] [Related]
70. Expression and association of HER2 with prognosis in early-stage (T1-T2N0M0) non-small cell lung cancer. Xia Q, Zhu Z, Wang J, Situ D, Zhou N, Jang W. Tumour Biol; 2012 Oct 12; 33(5):1719-25. PubMed ID: 22736332 [Abstract] [Full Text] [Related]
71. The challenge to bring personalized cancer medicine from clinical trials into routine clinical practice: the case of the Institut Gustave Roussy. Arnedos M, André F, Farace F, Lacroix L, Besse B, Robert C, Soria JC, Eggermont AM. Mol Oncol; 2012 Apr 12; 6(2):204-10. PubMed ID: 22483534 [Abstract] [Full Text] [Related]
72. Engagement of overexpressed Her2 with GEP100 induces autonomous invasive activities and provides a biomarker for metastases of lung adenocarcinoma. Menju T, Hashimoto S, Hashimoto A, Otsuka Y, Handa H, Ogawa E, Toda Y, Wada H, Date H, Sabe H. PLoS One; 2011 Apr 12; 6(9):e25301. PubMed ID: 21966491 [Abstract] [Full Text] [Related]
73. Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivo. Foy KC, Liu Z, Phillips G, Miller M, Kaumaya PT. J Biol Chem; 2011 Apr 15; 286(15):13626-37. PubMed ID: 21325276 [Abstract] [Full Text] [Related]
74. Plasmid DNA delivery into MDA-MB-453 cells mediated by recombinant Her-NLS fusion protein. Jeyarajan S, Xavier J, Rao NM, Gopal V. Int J Nanomedicine; 2010 Oct 05; 5():725-33. PubMed ID: 21042418 [Abstract] [Full Text] [Related]
75. The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies. Freudenberg JA, Wang Q, Katsumata M, Drebin J, Nagatomo I, Greene MI. Exp Mol Pathol; 2009 Aug 05; 87(1):1-11. PubMed ID: 19450579 [Abstract] [Full Text] [Related]
76. HER2 overexpression correlates with survival after curative resection of pancreatic cancer. Komoto M, Nakata B, Amano R, Yamada N, Yashiro M, Ohira M, Wakasa K, Hirakawa K. Cancer Sci; 2009 Jul 05; 100(7):1243-7. PubMed ID: 19432892 [Abstract] [Full Text] [Related]
77. Paradoxical concentration effect of a homodimerizing antibody against a human non-small cell lung cancer cell line. Kohler H, Bryan AJ. Cancer Immunol Immunother; 2009 May 05; 58(5):749-58. PubMed ID: 18820910 [Abstract] [Full Text] [Related]
78. Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2/neu and the EGFR-p185her2/neu complexes. Cai Z, Zhang G, Zhou Z, Bembas K, Drebin JA, Greene MI, Zhang H. Oncogene; 2008 Jun 19; 27(27):3870-4. PubMed ID: 18264138 [Abstract] [Full Text] [Related]
79. [Molecular pathogenesis of hepatocellular carcinoma: new therapeutic approaches and predictive pathology]. Kern MA, Breuhahn K, Schuchmann M, Schirmacher P. Pathologe; 2007 Jul 19; 28(4):261-8. PubMed ID: 17605064 [Abstract] [Full Text] [Related]
80. Trastuzumab and liposomal Doxorubicin in the treatment of mcf-7 xenograft tumor-bearing mice: combination does not affect drug serum levels. Waterhouse DN, Denyssevych T, Hudon N, Chia S, Gelmon KA, Bally MB. Pharm Res; 2005 Jun 19; 22(6):915-22. PubMed ID: 15948035 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]